Invictus RG’s DexCom DXCM Stock Holding History

Invictus RG’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-15,116	Closed	-$541K	–	46
2018 Q3	$541K	Buy	15,116 +2,696	+22%	+$83.6K	0.41%	56
2018 Q2	$295K	Buy	+12,420	New	+$263K	0.25%	117

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Invictus RG's DXCM Position: Q4 2018 in Review

Invictus RG sold out of DexCom (DXCM) in Q4 2018, closing a stake of 15,116 shares — an estimated $541K sold.

Invictus RG first reported a position in DXCM in Q2 2018 and held it in 2 quarters. The position peaked at $541K in Q3 2018. 415 funds tracked by Wall St. Rank hold DXCM as of Q4 2018.

Invictus RG reported no remaining DexCom position as of Q4 2018 after selling out during the quarter.
Invictus RG sold 15,116 DexCom shares in Q4 2018, an estimated $541K.
Invictus RG first reported a position in DexCom in Q2 2018 and held it in 2 quarters.
Invictus RG's DexCom position peaked at $541K in Q3 2018.
415 funds tracked by Wall St. Rank held DexCom as of Q4 2018.

Based on Invictus RG's 13F filing for Q4 2018, filed 13 Feb 2019.